Kabra Drugs
BSE: 524322
₹ 16.26▲ 0.4 (+2.52%)28 Oct, 03:29 pm IST
- P/E
- 5.1x
- 52-week range
- 15.3 – 35.52
- ROE
- 18%
- ROCE
- 21%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Kabra Drugs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)5.1 against a typical 34.3: cheaper than most peers (1st = cheapest).7th of 220
- Sales growth+546.4% against a typical +15.6% from a year earlier.2nd of 197
- Share price, 3 months−35% against a typical −0.5%.196th of 200
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 20 | 30 | 35 | 46 |
| Expenses | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 8 | 18 | 28 | 34 | 43 |
| Operating Profit | −0 | −0 | −0 | −1 | −0 | −1 | −0 | −1 | 2 | 2 | 1 | 3 |
| OPM % | — | — | — | — | — | — | — | −7.3% | 10.3% | 8% | 3.8% | 6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −0 | −1 | −0 | −1 | 0 | −1 | 2 | 3 | 1 | 3 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 16.7% | 1.5% | 25.4% | 25.4% |
| Net Profit | −0 | −0 | −0 | −1 | −0 | −1 | 0 | −1 | 2 | 3 | 1 | 2 |
| EPS in Rs | −0.3 | −0.25 | −0.84 | −1.25 | −0.4 | −0.54 | 0.16 | −0.21 | 0.78 | 1.08 | 0.45 | 0.89 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- 25%
- 5 Years
- —
- 3 Years
- —
- TTM
- 1,744%
Compounded Profit Growth
- 10 Years
- 67%
- 5 Years
- 97%
- 3 Years
- 155%
- TTM
- 823%
Stock Price CAGR
- 10 Years
- 12%
- 5 Years
- 33%
- 3 Years
- 66%
- TTM
- —
Return on Equity
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 5.1xEPS (12 months) ₹ 3.20Median P/E 28.1x
P/E (times)EPS (₹)
Prices are delayed and for information only. Nothing on this page is investment advice.